Type 2 diabetes mellitus, blood cholesterol, triglyceride and colorectal cancer risk in Lynch syndrome
S Ghazaleh Dashti, Wing Yan Li, Daniel D Buchanan, Mark Clendenning, Christophe Rosty, Ingrid M Winship, Finlay A Macrae, Graham G Giles, Sheetal Hardikar, Xinwei Hua, Stephen N Thibodeau, Jane C Figueiredo, Graham Casey, Robert W Haile, Steven Gallinger, Loic Le Marchand, Polly A Newcomb, John D Potter, Noralane M Lindor, John L Hopper Show all
British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2019
BACKGROUND: Type 2 diabetes mellitus and high total cholesterol and triglycerides are known to be associated with increased colorectal cancer risk for the general population. These associations are unknown for people with a germline DNA mismatch repair gene mutation (Lynch syndrome), who are at high risk of colorectal cancer. METHODS: This study included 2023 (56.4% female) carriers with a mismatch repair gene mutation (737 in MLH1, 928 in MSH2, 230 in MSH6, 106 in PMS2, 22 in EPCAM) recruited by the Colon Cancer Family Registry between 1998 and 2012. Weighted Cox regression was used to estimate the hazard ratios (HR) and 95% confidence intervals (CI) for the associations between self-report..View full abstract
Awarded by National Cancer Institute (NCI) of the National Institutes of Health (NIH)
Awarded by Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute
This work was supported by supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under Award Number U01 CA167551 and through NCI/NIH cooperative agreements with the following Colon Cancer Family Registry (CCFR) sites: Australasian Colorectal Cancer Family Registry (U01 CA074778 and U01/U24 CA097735), Mayo Colon Cancer Family Registry (U01/U24 CA074800), Ontario Familial Colorectal Cancer Registry (U01/U24 CA074783), Seattle Familial Colorectal Cancer Registry (U01/U24 CA074794), Hawaii Family Registry of Colon Cancer (U01/U24 CA074806 and R01 CA104132 to L LeMarchand), and CedarsSinai Medical Center Consortium (U01/U24 CA074799). Additional support for case ascertainment was provided from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute to Fred Hutchinson Cancer Research Center (Control Nos. N01-CN-67009 and N01-PC-35142, and Contract No. HHSN2612013000121), the Hawaii Department of Health (Control Nos. N01-PC67001 and N01-PC-35137, and Contract No. HHSN26120100037C), and the California Department of Public Health (contracts HHSN261201000035C awarded to the University of Southern California and HHSN261201000140C awarded to the Cancer Prevention Institute of California), the following U.S. state cancer registries: AZ, CO, MN, NC, NH, and by the Victorian Cancer Registry, Australia and the Ontario Cancer Registry, Canada. This study was also supported by the Australian National Health and Medical Research Council (NHMRC) Fellowships awarded to AKW, DDB (Career Development Fellowships), MAJ (Senior Research Fellowship) and JLH (Senior Principal Research Fellowship). DDB is also funded by a University of Melbourne Research at Melbourne Accelerator Program (R@MAP).